News Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
35.4 ^USD	+0.74%		-8.74%	+15.01%

Apr. 11	Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes	MT
Feb. 26	Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes	Apr. 11	MT
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026	Apr. 11	GL
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026	Apr. 11	AQ
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	GL
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	AQ
Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	Feb. 26	MT
Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating	Feb. 26	MT
Collegium Pharmaceutical's Q4 Adjusted Earnings, Revenue Increase	Feb. 23	MT
Collegium Pharmaceutical: Q4 Earnings Snapshot	Feb. 22	AQ
Transcript : Collegium Pharmaceutical, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q4 EPS $1.58, vs. Street Est of $1.26	Feb. 22	MT
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results	Feb. 22	GL
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results	Feb. 22	AQ
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024	Feb. 22	CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024	Feb. 08	GL
Deadline Dexterity: PTAB Has Authority To Issue Decisions After Statutory Deadline	Jan. 18	AQ
North American Morning Briefing : Bond Yields Rise -2-	Jan. 05	DJ
Truist Adjusts Collegium Pharmaceutical's Price Target to $37 From $31, Keeps Buy Rating	Jan. 04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Summary

Filters